Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of BNT314 plus pumitamig and chemotherapy in metastatic colorectal cancer
jRCT2031250532Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Nov 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised trial of GEN1059 and pumitamig in colorectal cancer (CRC), sponsored by BioNTech SE. Primary endpoints: Dose-limiting toxicities (DLTs), Treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
GEN1059pumitamig
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031250532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250532.